Good morning :)
$
₹
A

Adlai Nortye Ltd. American Depositary Shares

ANL

NASDAQ
A

Adlai Nortye Ltd. American Depositary Shares

ANL

NASDAQ
$9.630.26% (+0.02)
$
₹
$9.630.26% (+0.02)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Small Cap

With a market cap of $616.9M the stock is ranked 3128

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

2.81
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-0.66
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-124.77%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 7 analysts reports

Buy
7 analysts
Hold
0 analyst
Sell
0 analyst

Price Upside

+206.97%

Earnings Growth

+84.25%

Rev. Growth

+243.83%

See Detailed Forecast

Company Profile

Company Profile

Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies. Its RAS-targeting programs include AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate that delivers a pan-RAS(ON) inhibitor to tumors. Its immunotherapy programs include AN8025, a tri-functional fusion protein (aPD-L1 x CD86 variant x LAG3 variant) that modulates T-cells and antigen-presenting cells; AN0025, a small molecule EP4 antagonist; and AN4005, an oral small-molecule PD-L1 inhibitor. The company supports its pipeline through an immuno-oncology research and development platform with operations in the United States and China. Adlai Nortye Group Ltd. was formerly known as Adlai Nortye Ltd. and changed its name to Adlai Nortye Group Ltd. in July, 2026. Adlai Nortye Group Ltd. was founded in 2004 and is based in Singapore.
Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies. Its RAS-targeting programs include AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate that delivers a pan-RAS(ON) inhibitor to tumors. Its immunotherapy programs include AN8025, a tri-functional fusion protein (aPD-L1 x CD86 variant x LAG3 variant) that modulates T-cells and antigen-presenting cells; AN0025, a small molecule EP4 antagonist; and AN4005, an oral small-molecule PD-L1 inhibitor. The company supports its pipeline through an immuno-oncology research and development platform with operations in the United States and China. Adlai Nortye Group Ltd. was formerly known as Adlai Nortye Ltd. and changed its name to Adlai Nortye Group Ltd. in July, 2026. Adlai Nortye Group Ltd. was founded in 2004 and is based in Singapore.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
49.14
49.14
1Y Return
36.01%
36.01%
Buy Reco %
79.31
79.31
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
28.64
28.64
1Y Return
50.65%
50.65%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
42.33%
42.33%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
35.59
35.59
1Y Return
30.09%
30.09%
Buy Reco %
81.25
81.25
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
21.51
21.51
1Y Return
40.33%
40.33%
Buy Reco %
67.85
67.85
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 206.97% growth, versus a trailing 3-year CAGR of 4.71%.

2026
Current$9.61Baseline
Analyst Target - 1 year
Target$29.5+206.97%

All values in $

20232024202520262027$9.07$16.86$24.66Target+206.97%
2026
Current$9.61Baseline
Analyst Target - 1 year
Target$29.5+206.97%

All values in $

Revenue Forecast

Revenue Forecast

2025
Current$5Baseline
Forecast for Dec 2026
High$29.4+488%
Average$17.19+243.83%
Low$13.06+161.2%

All values in $ Million

20212022202320242025202645.7204.9905Low+161.2%Average+243.83%High+488%
2025
Current$5Baseline
Forecast for Dec 2026
High$29.4+488%
Average$17.19+243.83%
Low$13.06+161.2%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-1.17Baseline
Forecast for Dec 2026
High$-0.06+94.87%
Average$-0.18+84.25%
Low$-0.32+72.65%

All values in $

20212022202320252026N/AN/A-2.56-1.17Low+72.65%Average+84.25%High+94.87%
2025
Current$-1.17Baseline
Forecast for Dec 2026
High$-0.06+94.87%
Average$-0.18+84.25%
Low$-0.32+72.65%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

2.5
-8.5
7.3
-2.6
7.3
-2.6
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue0.740.74----2.5-7.347.34
Net Income-13.80-13.80-12.12--9.16-9.16-8.59--2.66-2.66
Net Profit Margin-1853.15%-1853.15%-----343.86%--36.34%-36.34%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Adlai Nortye Ltd. American Depositary Shares -2.81-
AbbVie Inc49.1450.450.58
Amgen Inc28.6421.552.77
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare ANL with any stock or ETF
Compare ANL with any stock or ETF
Comparing from
ANL
ABBV
AMGN
Loading...

Frequently asked questions

  1. Adlai Nortye Ltd. American Depositary Shares (ANL) share price today is $9.63 as of November 6, 2026 at 2:29 AM IST. The stock touched a day high of $9.75 and a day low of $8.93.

  2. Adlai Nortye Ltd. American Depositary Shares stock trades on NASDAQ under the ticker symbol ANL.

  3. Adlai Nortye Ltd. American Depositary Shares's market capitalization is $616.93M as of November 6, 2026 at 2:29 AM IST.

  4. Adlai Nortye Ltd. American Depositary Shares's price-to-earnings (P/E) ratio is N/A as of November 5, 2026.

  5. Adlai Nortye Ltd. American Depositary Shares's price-to-book (P/B) ratio is 2.81 as of November 5, 2026.

  6. Yes, You can buy Adlai Nortye Ltd. American Depositary Shares shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Adlai Nortye Ltd. American Depositary Shares shares in three steps: 1. Search Adlai Nortye Ltd. American Depositary Shares on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Adlai Nortye Ltd. American Depositary Shares trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Adlai Nortye Ltd. American Depositary Shares (ANL) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 1.0378 shares at the current price of $9.63.

Loading...